Friday 6 November 2026
Export TMO’s income statement to Excel — free account
Thermo Fisher Scientific Inc.
TMO Healthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.
- Revenue
- +9.13%
- EPS
- +8.64%
- Free cash flow
- +15.0%
- Total debt
- +22.8%
Quarter to September 2026, against a year earlier
693.03
16.09
+2.38%
Follow TMO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
32.61 | 26.98 | 26.93 | 35.55 |
P/S ratio |
4.90 | 4.05 | 4.01 | 5.27 | |
P/FCF ratio |
34.47 | 26.93 | 25.27 | 32.71 | |
P/Operating CF |
63.19 | 153.40 | 87.53 | 97.95 | |
P/B ratio |
4.09 | 3.52 | 3.53 | 4.56 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.48 | 4.86 | 4.77 | 5.97 | |
EV/EBITDA |
23.20 | 20.52 | 19.94 | 24.43 | |
EV/Operating CF |
31.24 | 26.51 | 24.53 | 30.33 | |
EV/FCF |
38.54 | 32.36 | 30.04 | 37.03 | |
Quick Ratio |
1.25 | 0.85 | 0.90 | 1.11 | |
Current Ratio |
1.89 | 1.53 | 1.55 | 1.81 | |
Net Debt/EBITDA |
8.63 | 14.16 | 12.09 | 10.70 | |
Debt/Assets |
32.49% | 35.37% | 34.62% | 34.24% | |
Debt/Equity |
0.67 | 0.77 | 0.74 | 0.71 | |
Asset Turnover |
0.43 | 0.43 | 0.43 | 0.44 | |
Operating CF/Net income |
1.76 | 0.72 | 1.22 | 1.48 | |
Capex/Depreciation |
(0.60) | (0.50) | (0.55) | (0.53) | |
Interest Coverage |
6.18 | 5.27 | 5.20 | 5.43 | |
Research and Development Expense of Revenue |
2.92% | 3.05% | 3.03% | 2.87% | |
Selling, General and Administrative Expense of Revenue |
19.26% | 19.82% | 19.45% | 15.35% | |
Intangible Assets out of Total Assets |
0.59 | 0.66 | 0.65 | 0.63 | |
Share Based Compensation of Revenue |
0.69% | 0.75% | 0.68% | 0.79% | |
Graham Net Nets |
(0.13) | (0.21) | (0.20) | (0.14) | |
Graham Number |
238.01 | 239.25 | 243.92 | 251.49 | |
Earnings Yield |
3.07% | 3.71% | 3.71% | 2.81% | |
Free Cash Flow Yield |
2.90% | 3.71% | 3.96% | 3.06% | |
Revenue per Share |
32.40 | 29.58 | 32.33 | 32.80 | |
Operating CF per Share |
9.17 | 3.20 | 5.73 | 6.89 | |
Capex per Share |
(1.16) | (0.99) | (1.20) | (1.18) | |
Free Cash Flow per Share |
8.01 | 2.22 | 4.53 | 5.71 | |
Cash per Share |
26.80 | 8.75 | 10.95 | 16.38 | |
Shareholders Equity per Share |
141.68 | 139.62 | 142.01 | 148.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
141.68 | 139.62 | 142.01 | 148.02 | |
Free Cash Flow |
3,019.00 | 825.00 | 1,679.00 | 2,114.00 | |
Working Capital |
13,518.00 | 7,695.00 | 8,296.00 | 11,445.00 | |
Capital Expenditures |
(438.00) | (367.00) | (446.00) | (436.00) | |
Net Current Asset Value |
(28,221.00) | (39,025.00) | (37,123.00) | (33,851.00) | |
EV/EBIT |
31.52 | 27.83 | 27.14 | 33.39 | |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.04 | |
Price to Operating Income |
28.20 | 23.16 | 22.83 | 29.49 | |
| Other line items | |||||
Average Receivables |
8,545.50 | 8,829.50 | 9,022.50 | 9,268.00 | |
Average Payables |
3,350.50 | 3,196.50 | 3,124.00 | 3,103.50 | |
Average Inventory |
5,201.50 | 5,360.00 | 5,593.00 | 5,694.00 | |
Average Assets |
103,832.00 | 106,161.00 | 107,202.00 | 108,626.50 | |
Average Common Equity |
51,483.00 | 50,648.50 | 51,581.50 | 52,896.50 |
Columns are period end dates · fundamentals updated 6 Nov 2026